Atypical mycobacteria are widespread in the environment and cause both local and disseminated disease. Prior to the HIV epidemic, pulmonary disease due to Mycobacterium kansasii has been most commonly reported in the USA and Western Europe, particularly in those with pre-existing lung pathology.' When found disseminated M kansasii infection was often associated with pancytopenia and immunosuppressive therapy.2 Contamination of clinical samples was well recognised, and led some authors to specify strict criteria before a diagnosis of M kansasii infection could be made. 3 However, the suggestion that M kansasii is virtually never a contaminant and that isolation from respiratory cultures is correlated with pulmonary disease has become more accepted with the advent of the HIV epidemic. 45 With the rising prevalence of HIV infection there has been an increase in the number of reports of all the mycobacterial diseases, but the proportion of Review of antimicrobial sensitivities (table 1) indicates that all isolates were sensitive to ethambutol and nine of 10 were sensitive to rifampicin. All were resistant to isoniazid and pyrazinamide. Six isolates were tested against ciprofloxacin and all were fully or partially sensitive.
All cases were treated initially with at least two drugs to which their M kansasii infection was sensitive. By April 1994 three of the 10 patients had died; M kansasii infection is felt to have contributed partially to two deaths, although both patients had multiple, advanced AIDS related illnesses. Patient 8 had treatment for M kansasii withdrawn after one week and died within one month of disseminated lymphoma. The remainder were alive one to 15 months after diagnosis.
Discussion
This report details a series of M kansasii disease associated with HIV infection in the Alalaise Abscess Blood UK. Like infection with M avium complex, in this study M kansasii disease occurred in those with severe immunosuppression. Presentation was non-specific; fever and malaise were common, although specific symptoms were usual in patients with respiratory infection. In contrast with the experience of Levine et al" chest radiographs were often normal in patients with pulmonary disease. This lack of cavitation and fibrosis has been noted in other series'2-14 and presumably reflects the underlying level of immunosuppression.
In patients with AIDS, initial respiratory or gastrointestinal isolation of other atypical mycobacteriae is frequently followed by widespread dissemination of the infection. From the antimicrobial sensitivities presented, we would continue to recommend the initial use of rifampicin/rifabutin and ethambutol as first line treatments. All patients in this series had isoniazid resistant M kansasii, an observation seen partially or fully in a number of other reviews.5 11 12 Thus, in contrast to the recommendations of the American Thoracic Society'7 it would seem sensible not to include isoniazid in a treatment regimen and that if use of a third drug is necessary, to consider one of the newer quinolones. Although only a limited number of isolates were tested against clofazamine (n = 2) and clarythromicin (n = 1), as a result of the favourable sensitivities obtained, these drugs could also be considered in patients intolerant or failing first line treatment.
In reviewing previously reported in vitro sensitivity of M kansasii to sulphur based drugs, sulphamethiazole has been recommended as a treatment option'8 and has proved efficacious in HIV infected patients not responding to other treatment.'9 However, in the dosage used in prophylactic treatment of P carinii pneumonia sulphamethiazole seems to offer little protection against the development of M kansasii infection.
